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Abstract
Mesenchymal stem cells (MSCs) are non-hematopoietic multipotent stem cells with self-
renewal properties and ability to differentiate into a variety of mesenchymal tissues.
This chapter overviews effects of hypoxia on MSCs, makes it promising therapy to
various diseases. Cultivation of MSCs under hypoxic condition results in variety of
outcome that is important to be noted in clinical use. In most studies, hypoxic condition
appears to increase proliferation, differentiation, and immune regulatory performance
of MSCs without affecting its characteristic. Those benefits are therefore utilized in
clinical application. However, there are also studies that report on negative effects of
hypoxia in MSCs such as chromosomal instability. Molecular mechanism of MSCs in
hypoxic condition is provided for better understanding, which is crucial for further
development with better outcome.
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1. Introduction
In these days, stem cell therapy is becoming more believable in treating degenerative diseases
compared to conventional medicine. Various diseases such as diabetes, myocardial infarction,
spinal cord injury, stroke, and Parkinson’s and Alzheimer’s diseases have become more prevalent
with increasing life expectancy. It has been estimated that in the United States alone, ~128 million
individuals would benefit from regenerative stem cell therapy during their lifetime. Mesen-
chymal stem cells (MSCs) have been highly utilized to treat degenerative diseases among other
stem cells. These cells are found in tissues such as bone marrow, adipose tissue, umbilical cord,
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and dental pulp. Self‐renewal and multipotency are the key features of MSCs that make it
promising tool. These properties have raised interest on researchers for finding appropriate
method to optimize the genetic and environmental factors, which later enhance the biological
activities of MSCs.
Many researches have been conducted in the last two decades to study the complex processes
in stem cell maintenance. The role of hypoxic conditions (usually 2–9% O2 concentration) on
stem cell biology is very interesting subject due to its beneficial effects. Thus, cultivation of
MSCs under hypoxia is currently studied to obtain better understanding, as well as further
development to generate better outcome.
2. Mesenchymal stem cell
About 130 years ago, German pathologist Conheim proposed the presence of non‐hemato‐
poietic stem cells in the bone marrow that contributes to wound healing in numerous periph‐
eral tissues. Later in the early 1970s, Friedenstein and colleagues demonstrated that the rodent
bone marrow had fibroblastoid cells with clonogenic potential in vitro [1, 2]. In the study, after
the non‐adherent cells were removed a few hours later, spindle‐like cells, which were mor‐
phologically heterogeneous, appeared to attach to the plastic, capable of forming colonies.
These cells could also make bone and reconstitute a hematopoietic microenvironment in
subcutaneous transplants. Moreover, they could regenerate heterotopic bone tissue in serial
transplants, thus indicated their self‐renewal potential. Over the years, many studies have
investigated these findings and found that these cells were also present in the human bone
marrow and could be sub‐passaged and differentiated in vitro into a variety of the mesenchy‐
mal lineages such as osteoblasts, chondrocytes, adipocytes, and myoblasts [3–7]. It has been
further renamed as “mesenchymal stem cell” or MSC [4].
MSCs or MSC‐like cells are also found in fat, umbilical cord blood, amniotic fluid, placenta,
dental pulp, tendons, synovial membrane, and skeletal muscle, yet the complete equivalency
of such populations remains unclear [8–16]. Characteristic of MSCs according to The Interna‐
tional Society for Cell Therapy [17] consists of (1) adherence to plastic in standard culture
conditions; (2) expression of the surface molecules CD73, CD90, and CD105 in the absence of
CD34, CD45, HLA‐DR, CD14 or CD11b, CD79a, or CD19 surface molecules; and (3) a capacity
for differentiation to osteoblasts, adipocytes, and chondroblasts in vitro. These criteria were
established to standardize human MSC isolation but may not apply uniformly to other species.
For instance, marker expression and behavior in murine MSCs were different compared to
human MSCs [18]. Certain in vivo surface markers may no longer be expressed after Trans‐
plantation, although new markers are obtained during expansion. In study done by Jones et
al., MSC uniformly expressed HLA‐DR (a marker that should not be expressed on MSCs by
the above definition) while also expressing CD90 and CD105, adhering to plastic in culture,
and differentiating into osteoblasts, adipocytes, and chondroblasts [19]. Indeed, clear defini‐
tion of MSC‐specific characteristics is difficult to apply in both human and animal models.
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3. Hypoxia in mesenchymal stem cell
Numerous in vitro studies have been conducted in the last two decades to observe the complex
processes in stem cell maintenance. However, the role of physiologically hypoxic conditions
(usually 2–9% O2 concentration) on stem cell biology received very little attention. O2 concen-
tration is an environmental factor that plays a vital role on stem cell fate and function [20].
Stem cells are typically cultured under the ambient O2 concentration without paying attention
to the metabolic milieu of the niche in which they normally grow [21]. The effects of different
O2 levels in MSC culture were first studied in 1958, when Cooper et al. and Zwartouw and
Westwood observed that some cells proliferated more rapidly under low O2 tension levels
compared to normal atmospheric levels [22, 23]. MSCs are present in perivascular niches in
close association with blood vessels in virtually all tissues [11, 16, 24] and have been compared
to pericytes [25]. Even though MSCs are located close to vascular structures, the different
tissues where these stem cells are found exhibit low oxygen tensions [26–29]. Therefore, it is
possible that maintaining MSCs in an undifferentiated state may require a hypoxic environ-
ment, in addition to other factors.
The higher O2 concentration might cause environmental stress to the in vitro cultured MSCs.
Recent studies have presented significant evidences regarding the negative outcome under
ambient O2 concentration on MSCs, including early senescence, longer population doubling
(PD) time, DNA damage [30, 31], and poor engraftment following transplantation [32, 33].
These have shown the influential effect of O2 concentration on MSCs biology and raised serious
concern over its therapeutic efficiency and biosafety. Thus, the effect of different O2 concen-
tration on MSCs biology is further discussed based on recent research outcomes.
4. Characteristic of MSCs in hypoxic condition
As described above, MSC immunophenotype is characterized by the expression of CD73,
CD90, CD105, CD106, CD146, and MHC class I molecules, and the absence of markers such as
CD45 and CD34 or MHC class II molecules [17]. Many studies suggest that hypoxia has no
effect on MSCs characteristic, indicated by surface markers. According to one study by
Holzwarth et al., there were no significant differences in the expression of cell surface markers
after 14 days of culture at 1% when compared to 20% of O2 [34]. Referring to study carried out
by Nekanti et al., WJ-MSCs cultured under both hypoxia and normoxia for 10 passages were
positive for CD44, CD73, CD90, CD105, and CD166 and negative for CD34, CD45, and HLA-
DR, and there was no significant difference between the two populations [35]. These results
are also supported by study carried out by Widowati et al. The surface marker of WJ-MSCs of
P4 and P8 both normoxic and hypoxic 5% O2 were not significantly different. WJ-MSCs were
positive for CD105, CD73, and CD90 and negative for CD34, CD45, CD14, CD19, and HLA-II
[36].
Morphology changes are also documented in MSCs under hypoxia. Referring to Nekanti et
al., WJ-MSC cultured under hypoxia showed a higher amount of large, flattened cells both at
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early and late passages, compared to normoxic cultures. The enlargement in cell size under
hypoxia might be due to a natural response to low oxygen, in which increased surface area
would allow for an increase in oxygen diffusion rate [35].
5. MSCs proliferation in hypoxic condition
Capability for self-renewal is a key feature of stem cells. An increased proliferation rate is
necessary for more efficient use of stem cells in regenerative therapies. Fehrer et al. demon-
strated that bone marrow-derived MSCs (BM-MSCs) cultured in 3% O2 concentration showed
significant increased in vitro proliferative lifespan, with ~10 additional population doublings
(PDs) (28.5 ± 3.8 PD in 20% O2 and 37.5 ± 3.4 PD in 3% O2) before reaching senescence compared
to cells cultured in the ambient O2 environment [31]. In addition, early passaged MSCs cultured
in hypoxic conditions also exhibit increased proliferative lifespan along with significant
difference in population doubling [30]. Furthermore, it is possible to harvest more than
1 × 109 MSCs from the first five passages cultured in 3% O2, whereas in ambient condition only
2 × 107 cells can be obtained [30]. Higher in vitro expansion rate in hypoxic conditions has also
been reported by other researchers [37–39]. Such in vitro culture environment also allows to
maintain a higher proportion of rapidly self-renewing MSCs for a longer period of time [40].
Other study showed that the increased hypoxic (O2 2.5%) condition was the best microenvir-
onment for stem cell proliferation compared to normoxic and hypoxic (O2 5%) for cells at a
high passage (P7, P8) [41].
However, various responses of stem cells under hypoxia have been reported [42]. Those
differences in cellular responses on hypoxia might be associated with degrees and durations
of hypoxia, as well as other cell conditions. Oxygen tension in the stem cell niche for MSCs is
suggested to be various from 1 to 7% [43]. A study by Holzwarth et al. showed that rates of
MSCs proliferation were reduced after 7 days of culture under hypoxia at 21, 5, 3, and 1% O2.
In their study, only 1.37% of the cells entered the G2/M phase in hypoxic cultures (1% O2) after
7 days, compared to 2.50% at hyperoxic culture (21% O2). Reduced O2 concentrations were
therefore confirmed to inhibit cell proliferation as indicated by reduced number of cells in the
G2/M phase [34].
6. Chromosomal stability of MSCs in hypoxic condition
Some recent studies have found that human mesenchymal stem cells (hMSCs) retained
chromosomal stability following long-term culture in vitro [44–46]. Hypoxic environments
have shown to increase mutation frequencies in cancer cell lines and trigger genomic rear-
rangements [47, 48]. It is suggested that oxygen concentration has a major impact on karyotypic
aberration. Referring to study of Ueyama et al., chromosomal instability is associated with
repeated cell division. A high frequency of chromosomal abnormality breakpoints in common
fragile sites (CFSs) was detected by karyotypic analysis (e.g., 2q33, 7q11, 7q36, 8q22.1, 8q24.1,
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11p15.1, 19q13) [49]. Generally, chromosomes have fragile sites that are prone to exhibiting
gaps and breaks during metaphase [50], in which chromosome rearrangement occurs in
cultured cells. Fragile sites are categorized into two main classes, common and rare, according
to their frequency in the population [51]. In Ueyama study, several genes involved in regulation
of the cell cycle, transcription and cell adhesion, are located in that region with a frequency of
6, 5, and 2%, respectively. In particular, the 11p15.5 domain known as an important tumor
suppressor gene region such as tetraspanin 32 (TSPAN32) and tumor-suppressing subtrans-
ferable candidate 4 (TSSC4) is present in this region. Alterations in this region have been
associated with some neoplasia. It is suggested that the deletion of contiguous genes may
induce a multisystem developmental disorder and that these alterations might influence
normal functioning and cell survival.
Sex chromosome aneuploidy was also one of the most observed aberrational karyotypes.
Frequency of sex chromosome in cultured lymphocytes was significantly higher in females
than in males, and that loss of Y chromosomes correlated with age in human bone marrow
cells [52, 53]. There are several factors influencing karyotypic stability such as hypoxic culture
conditions, donor age, and multiple passages. Karyotypic aberrations increased with passage
number and hMSCs undergo spontaneous transformation with tumorigenic potential,
especially in later passages under hypoxic culture conditions in hMSCs of elderly donors [49].
Shortly, monitoring of chromosomal stability in culture expanded hMSCs is required prior to
exposure to human beings, in order to detect mutations and potentially immortalized clones
and to prevent transplant-associated tumor formation.
7. MSCs plasticity in hypoxic condition
The multilineage potential of MSCs is one of the reasons underlying their use in regenerative
medicine [54]. Results of MSC differentiation into other lineages diverse according to several
studies [34, 55, 56]. Some in vitro studies have shown that cultures with low O2 concentrations
stimulated cells to differentiate into adipogenic, osteogenic, or chondrogenic cells. Previous
study showed that Rat mesenchymal stem cells (rMSCs) cultured in 5% oxygen produced more
bone than cells cultured in 20% O2 throughout their cultivation time, as indicated by increased
markers of osteogenesis, including alkaline phosphatase activity, calcium content, and von
Kossa staining. These markers were usually elevated above basal levels when cells were
switched from control to low oxygen at first passage and decreased for cells switched from
low to control oxygen [57]. Hypoxia appears to exert a potent lipogenic effect independent of
PPAR-γ2 maturation pathway [58]. The level of differentiated antigen H-2Dd and the number
of G2/S/M phase cells increased evidently under 8% O2 condition. Also, the proportion of wide,
flattened, and epithelial-like cells increased significantly in MSCs. When cultured in adipo-
genic medium, there was a fivefold to sixfold increase in the number of lipid droplets under
hypoxic conditions compared with that in normoxic culture. Oct4 was downregulated under
8% O2 condition but still expressed after adipocyte differentiation in normoxic culture and
treated with hypoxia-mimicking agents, cobalt chloride (CoCl2) and deferoxamine mesylate
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(DFX). These findings indicate that hypoxia enhances MSC differentiation and hypoxia and
hypoxia-mimicking agents generate different effects on MSC differentiation [59].
Conversely, some others have reported suppressive effects of low O2 tension levels on the
plasticity of MSCs. Differentiation capacity into adipogenic progeny was diminished, and no
osteogenic differentiation was detected at 3% oxygen. In turn, MSC that had previously been
cultured at 3% oxygen could subsequently be stimulated to successfully differentiate at 20%
oxygen [31]. Temporary exposure of MSCs to hypoxia resulted in (i) persistent (up to 14 days
postexposure) downregulation of cbfa-1/Runx2, osteocalcin, and type I collagen and (ii)
permanent (up to 28 days postexposure) upregulation of osteopontin mRNA expressions [60].
Another study by Widowati et al. showed both nor-WJ-MSCs and hypo-WJ-MSCs differenti-
ated to osteocytes, chondrocytes, and adipocytes, although there was no significant difference
among treatments [36]. Study conducted by Georgi et al. showed that molecular fingerprints
of human MSCs, primary chondrocytes, and MSC/primary chondrocytes coculture differ
when cultured in either normoxic (21% O2) or hypoxic (2.5% O2) conditions [61]. In the study,
cartilage formation increased in cocultures of MSCs and primary chondrocytes was lost when
the cells were cultured under hypoxia which was associated with a decrease in the mRNA
expression of the chondrogenic marker SOX9 and FGF-1. This coincided with a significant
decrease in lipids. Lipid profiles of normoxic and hypoxic cultures are different. The improved
cartilage formation in cocultures of MSCs and chondrocytes may employ soluble factors,
including small molecules, lipids, or proteins [62]. Lipids such as phospholipids, cholesterol,
and diacylglycerols play significant roles in cellular signaling, membrane integrity, and
metabolism [63]. Recent study described that short-term changes in sphingolipid metabolism
resulted in long-term effects on the chondrogenic phenotype, and the stimulation of chondro-
cytes with acylceramidase improves cartilage repair and MSC differentiation [64].
8. Immunomodulatory effects of MSCs in hypoxic condition
One of the key factors of MSC in therapeutics development is their known anti-inflammatory/
immunomodulatory properties. Clinical studies showed efficacy of MSC at inhibiting lethal,
immune-based condition of graft versus host disease [65–70]. It has been reported that MSCs
derived from adipose, bone marrow, and placenta have the capability to recover ischemic
injury by increasing vascularization and reducing inflammation in ischemia-injured hindlimb,
lung, heart, and brain [71–73]. Thus, these cells have been used in clinical trials to treat ischemic
disease [74]. MSCs produce a broad variety of cytokines, chemokines, and growth factors that
may potentially be involved in tissue repair. Hypoxia increases the production of several of
these factors, although different responses are also noted in few studies. Referring to Chang
et al., hypoxic preconditioning enhances the capacity of the secretome obtained from cultured
human MSCs to release several of these factors and the therapeutic potential of the cultured
MSC secretome in experimental TBI [75].
One of the most studied mechanisms of inflammation-induced MSC activity is treatment with
interferon gamma (IFN-γ). This cytokine is usually secreted during inflammatory Th1 immune
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responses that are associated with autoimmunity mediated by cellular means, such as CD8 T
cells and NK cells, which commonly occur in multiple sclerosis, diabetes type 1, and rheuma-
toid arthritis [76]. Treatment of IFN-γ in MSC has been reported to enhance the immunosup-
pressive activity through stimulation of the enzyme IDO [77–80]. MSC expression of the
tryptophan-catabolizing enzyme indolamine 2,3 deoxygenase (IDO) was markedly upregu-
lated under hypoxia [81]. IDO is critical in immune regulation by MSC through induction of
T cell anergy [82] and stimulation of T regulatory cells (T-regs) [83, 84].
Moreover, IFN-γ induced secretion of other inhibitors of inflammation by MSCs, including the
complement inhibitor factor H [85], as well as the immunomodulatory molecules TGF-β and
HGF [86]. At a functional level, Noone et al. demonstrated that IFN-γ pretreatment of MSC
resulted in protection of MSCs from NK-mediated killing via upregulation of prostaglandin
E (PGE)-2 synthesis [87]. IFN-γ, along with necrosis factor-alpha (TNF-α), IL-1α, and IL-1β,
induces Gal-9 in MSC [88].
Another inflammatory mediator known to induce regenerative activities in MSC is the
macrophage-derived cytokine TNF-α. Pretreatment of TNF-α in MSCs provided superior
angiogenic activity in vitro, as indicated by expression of VEGF, as well as in vivo in an animal
model of critical limb ischemia, as compared to untreated MSCs [89]. In other study, TNF-α
preconditioning increased proliferation, mobilization, and osteogenic differentiation of MSCs
and upregulated bone morphogenetic protein-2 (BMP-2) protein level. Osteogenic differen-
tiation of MSC induced by TNF-α was partially inhibited after BMP-2 knockdown by siRNA
[90]. Lipopolysaccharide and toll-like receptor (TLR) agonists, as activators of innate immunity,
are also responsible for regenerative activity of MSCs by inducing paracrine factors secretion
such as VEGF [91]. IFN-γ and TLR also upregulate the glucocorticoids production, which
decreases T cells stimulated by radiotherapy in colonic mucosa [92].
Akiyama et al. reported that MSCs induced T cell apoptosis via the Fas/FasL pathway [93].
Telomerase improved immunomodulatory properties of MSCs by upregulating FasL expres-
sion [94]. Dental follicle cells and cementoblasts have been reported to trigger apoptosis of
ameloblast-lineage cells, as well as Hertwig’s epithelial root sheath (HERS)/epithelial rests of
Malassez (ERM) cells, via the Fas/FasL pathway during tooth development [95]. FasL regulated
the immunomodulatory properties of Human gingiva-derived mesenchymal stem cells
(hGMSCs), which is promoted by hypoxia. However, the underlying pathways of such event
remain unclear. Further studies regarding the pathways involved in hGMSC-mediated
immunomodulation are encouraged.
9. Molecular mechanism of MSCs in hypoxic condition
O2 concentration in the stem cell niche (usually 2–9% O2) is considered a driver of cell function
[20]. Hypoxia plays a vital role in maintaining homeostasis within the body from the early
stage of embryonic development. It facilitates proper embryonic development, maintains stem
cell pluripotency, induces differentiation, and regulates the signaling of multiple cascades,
including angiogenesis [96]. In hypoxic conditions, these functions are regulated by several
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transcription factors such as hypoxia-inducible factors (HIFs), prolyl hydroxylases (PHDs),
factor-inhibiting HIF-1 (FIH-1), activator protein 1 (AP-1), nuclear factor (NF)-κB, p53, and c-
Myc [97]. Although interaction among all of the transcription factors is required for cellular
response, HIFs (especially HIF-1) are the key regulators of cellular response to hypoxia [98].
The discovery of HIF-1a by Greg Semenza provided profound insight into the cellular
mechanisms that control hypoxic adaptation [99–101].
Generally, under hypoxic conditions, low O2 level suppresses the prolyl hydroxylation that
leads to HIF-1α accumulation and nuclear translocation [102]. After nuclear translocation, it
binds with HIF-1β to form the heterodimer. Then, the HIF-1 heterodimer binds to a hypoxia-
response element (HRE) in the target genes, associated with coactivators such as CBP/p300,
and regulates the transcription (Figure 1) of as many as 70 genes involved in metabolism,
angiogenesis, invasion/metastasis, and cell fate [103].
Figure 1. Regulation of hypoxia in MSCs. HIF, hypoxia-inducible factor; HPH, HIF-prolyl hydroxylases; HPE, HIF-
prolyl hydroxylases; HRE, hypoxia-response element; CDK, cyclin-dependent kinase; VEGF, vascular endothelial
growth factor; VEGFR, vascular endothelial growth factor receptor; IGF, insulin-like growth factor; TNF, tumor ne-
crosis factor; PGE-2, prostaglandin E-2; Gal9, galectin-9. The prolyl hydroxylation process is suppressed due to lack of
O2 that leads HIF-1α accumulation and nuclear translocation after nuclear translocation, and it binds HIF-1β to form
the heterodimer. Then, the HIF-1 heterodimer binds HRE in the genes target, associated with coactivators such as CBP/
p300, and regulates the transcription of as many as 70 genes involved in proliferation, differentiation, and immunomo-
dulatory.
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In 2007, iPSCs were discovered by Shinya Yamanaka and colleagues, and the subsequent
identification of the necessary transcriptional programs was required to maintain stem cells in
a pluripotent state [104, 105]. The measurement of low partial pressures of oxygen in various
stem cell niches raises question whether HIF-1a and iPSCs pathways were converged. It was
described initially in Embryonic stem cells (ESCs) [106], hematopoietic stem cells (HSCs) [107],
neural stem cells (NSCs) [108], and cancer stem cells (CSCs) [109], which now further expanded
to include iPSCs [110]. Remarkably, Yamanaka first reprogrammed fibroblasts to iPSCs using
only four transcription factors (Oct4, Sox2, c-Myc, and Klf4) [105] in the same year that Oct4
was shown to be a specific target gene of HIF-2a [111]. The correlation between HIF-2a and
Oct4 has been proposed as underlying mechanism of stem cells response to hypoxic conditions
in their niche and direct modification of stem cell function by low O2. HIF-2a expression has
recently been investigated in several stem cell lineages, and Oct4 expression is tightly regulated
throughout embryogenesis. Loss or even decrease in Oct4 expression leads to differentiation
[112]. Oct4 works in concert with Nanog and Sox2 to maintain stem cell identity and repress
genes that promote differentiation [113]. The recent identification of HIF-2a upregulation by
Oct4 in CSCs and ESCs underscores the importance of this axis in maintaining stemness in
both development and disease.
It is known that phosphorylation of protein kinase B (Akt), a downstream gene of phosphati-
dylinositol 3-kinase (PI3K) signaling pathway, is an important step in signaling pathways that
mediate cell proliferation [114, 115]. In PI3K/Akt pathway, a large number of substrates are
phosphorylated, including HIF-1 [116]. Referring to study done by Rosová et al., the preculture
of MSCs in hypoxia prior to injection activated the PI3K/Akt signaling pathway while main-
taining their viability and cell cycle rates [117].
Hypoxia-mediated MSC differentiation by reducing apoptosis via activating the PI3K/Akt/
FoxO pathway. Referring to Wang et al., MSCs underwent apoptosis upon induction for
chondrogenic differentiation [118]. Apoptosis has been demonstrated as a general phenom-
enon that occurs during endochondral differentiation of chondrocytes [119]. One study
demonstrated that chondrocytes progression to endochondral ossification employed higher
FAS receptor and caspase protein as indicators of apoptosis [120]. Other studies showed that
both the Wnt/beta-catenin and Indian hedgehog (Ihh) signaling pathways play important roles
in endochondral ossification. Beta-catenin is needed at upstream of Ihh signaling for chon-
drocyte survival and inhibition of apoptosis [121]. The expression of Sox9, col2a1 and aggrecan
in prechondrogenic cells 30 and chondrocytes 14 is regulated by PI3K/Akt pathway. It has also
been demonstrated that PI3K/Akt regulated col2a1 and aggrecan by modulating Sox9 expres-
sion and transcriptional activity in nucleus pulposus cells 31.
Lee et al. [122] showed novel pathway for hypoxia-induced proliferation and migration in
human mesenchymal stem cells that employ HIF-1α, FASN, and mTORC1O. Hypoxia
treatment stimulates UCB-hMSC proliferation, along with the expression of two lipogenic
enzymes: fatty acid synthase (FASN) and stearoyl-CoA desaturase-1 (SCD1). FASN is a key
enzyme in UCB-hMSC proliferation and migration. Hypoxia-induced FASN expression was
regulated by the HIF-1α/SCAP/SREBP1 pathway. Mammalian target of rapamycin (mTOR)
was phosphorylated by hypoxia, whereas inhibition of FASN by cerulenin suppressed
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hypoxia-induced mTOR phosphorylation, as well as UCB-hMSC proliferation and migration.
Hypoxia-induced proliferation and migration are significantly inhibited by raptor small
interfering RNA. Hypoxia-induced mTOR also regulates CDK2, CDK4, cyclin D1, cyclin E,
and F-actin expression as well as c-myc, p-cofilin, profilin, and Rho GTPase. Moreover,
hypoxia-induced FASN stimulates FFA production as well as proliferation and migration.
Several studies reported that FAS and FA derivatives inhibited and uncoupled oxidative
phosphorylation of various cells [123–125]. Palmitic acid treatment rescues inhibition of mTOR
phosphorylation as well as restriction of UCB-hMSC proliferation and migration. Change in
cellular metabolite ratios may be another pathway, in addition to the HIF1a/SCAP/SREBP1
pathway, involved in the regulation of lipid metabolism in UCB-hMSCs. Some studies reported
that alteration of cellular metabolite ratios, such as NADP/NADPH, by hypoxia has also an
important role in the regulation of various stem cell functions such as cell cycle and self-
renewal activities [126, 127].
10. Hypoxic MSCs in clinical application
MSCs possess anti-inflammatory/immunomodulatory properties, which are utilized in
therapeutics development. Clinical studies on efficacy of MSCs have been shown to inhibit
lethal, immune-based condition of graft versus host disease [65–70]. Moreover, MSCs derived
from adipose, bone marrow, and placenta have the capability to recover ischemic injury by
increasing vascularization and reducing inflammation in ischemia-injured hindlimb, lung,
heart, and brain [71–73, 128]. These cells have been used in clinical trials to treat ischemic
disease [74], and the safety of MSCs has been evaluated [129, 130]. There are several modified
approaches, which have been proposed to improve the effect of MSCs on ischemia-related
disease, such as over expression of angiogenesis-related genes such as bFGF on MSCs [131],
combination with other cells such as endothelial cells [84], antioxidants such as melatonin
[132], serum deprivation [72], and cell spheroids [133].
From isolation to engraftment, the MSCs usually pass through two different phases, consist-
ing of in vitro culture condition (from isolation to transplantation) and in vivo or physiological
condition (before isolation and after transplantation). At present, most of the expansion
procedures of MSCs are performed under ambient O2 concentration, where cells are exposed
to 20% O2, which is ~4–10 times more than the concentration of O2 in their natural niches [134,
135]. Maintaining genetic stability has been a challenge during in vitro expansion of MSCs.
Increased rates of aneuploidy, double-stranded DNA breakdown, and faster telomere short-
ening have been reported for MSCs cultured in ambient condition [30]. According to recent
review, major causes behind aneuploidy were defective spindle assembly checkpoint, centro-
some amplification, and merotelic attachments [136], which are caused by ROS [137]. ROS also
acts in acceleration of telomere shortening and DNA breakdown [138, 139]. Correlation
between telomere shortening and aneuploidy in embryonic and hepatocellular carcinoma cells
has also been reported in recent studies [140, 141]. The higher ROS production due to the
increased mitochondrial respiration during expansion of MSCs in ambient O2 concentration
might be the cause behind genetic instability in them. However, cells undergo anaerobic
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respiration during hypoxia, which lowers the ROS concentration within the cells. This might
reduce the DNA damage, telomere shortening, and aneuploidy which in return may increase
the biosafety of stem cell-based therapy.
The ability of stem or progenitor cells to home and engraft into target tissues after transplan-
tation is the key to succeed in clinical application. The degree of homing and engraftment of
MSCs in adult recipients is very low [142–144]. Hypoxic culture conditions may also provide
a solution for more efficient engraftment. Recently, early passaged mouse BM-MSCs showed
better engraftment than late passaged mouse BM-MSCs in in vivo model [145]. In other study,
hypoxic preconditioned murine MSCs also enhanced skeletal muscle regeneration and
improved blood flow and vascular formation compared to normoxic condition [146]. Further-
more, hypoxic conditions cause MSCs to grow faster [30] while maintaining a higher number
of rapidly self-renewing cells [40]. Hypoxic environment also upregulated chemokine
receptors CXCR4, CXCR7 and CX3CR1 [147, 148], and they may facilitate tissue-specific
trafficking of MSCs. Thus, sufficient numbers of MSCs with a higher fraction of rapidly self-
renewing cells are suggested, and highly expressed chemokine receptors on their surface can
be obtained from the early passages of hypoxic cultures, which could increase the efficiency
of damaged tissue-specific migration and engraftment following transplantation.
MSCs cultured under hypoxic conditions also increased in vascular endothelial growth factor
receptor 1 (VEGFR1) expression and VEGF- or placental growth factor (PLGF)-dependent
migration (Okuyama et al., 2006). Preconditioning with oxygen and combined glucose depletion
also increased the survival of stem cell antigen (Sca)-1þ cells via PI3K/Akt-dependent caspase-3
downregulation and thereby increased the engraftment rate [149]. In addition to the increase in
migration and survival, MSCs with hypoxic preconditioning have also been shown to enhance
revascularization after transplantation for hindlimb ischemia [117]. Therefore, culturing MSCs
in hypoxic conditions can also be considered as a solution for tissue-specific engraftment.
Hypoxia-stimulated immune regulation of MSCs has been observed in the situation of
allogeneic use of BM-MSCs for stimulation of therapeutic angiogenesis. Recent study showed
hypoxia-conditioned BM-MSCs from B6 mice repair limb of Balb/c mice compared to normoxic
MSCs. Engraftment in allogeneic recipients increased by decreasing NK cells cytotoxicity and
the accumulation of host-derived NK cells when transplanted in vivo. These allogeneic
hypoxia-treated BM-MSCs increased CD31+ endothelial cells and αSMA+ and desmin + mus-
cle cells, thereby enhancing angiogenesis and restoring muscle structure. Moreover, anti-NK
antibodies along with normoxic MSCs enhanced angiogenesis and prevented limb amputation
in allogeneic recipients with limb ischemia [150].
Some studies have shown that MSC transplantation contributes to tumor formation in vivo [24,
151, 152], whereas Furlani et al. reported that cultured MSCs with spontaneous transforma-
tions had no functional effects after intracardiac transplantation [153]. Further studies regard-
ing tumorigenicity and safety of the stem cell-based products are encouraged. However,
complexity of cell therapy requires more standards for advanced medicinal products [154].
Thus, especially in the field of regenerative medicine, concrete and specific standards and
governmental support systems are necessary to promote their production [154].
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11. Perspective of hypoxic MSCs
Hypoxic condition has been confirmed to enhance MSCs proliferation, differentiation, and
immune regulatory performance. However, some studies have also reported opposite and
negative effects. Different outcomes in each study raise interest in availability of more
appropriate methods for cell cultures, which require further study in standardizing the culture
of MSCs for use in cell therapy. Optimal conditions for the culture of MSCs have not yet been
clearly defined, and it is very crucial to precisely determine the effects of hypoxia on MSCs
differentiation, proliferation, and morphology, among other aspects. Moreover, hypoxic MSC-
based therapies require a complete understanding of stem cell molecular mechanism. The
clarity in stem cell regulation is important for further development such as periodic monitoring
of chromosomal stability in culture prior to exposure to human to detect mutations and to
prevent transplant-associated tumor formation, and also genetic engineering of physiology of
MSCs to acquire better outcome.
12. Conclusion
The growing interest in the potential application of MSCs in regenerative medicine was
followed by the several studies measuring the effects of low O2 levels on the behavior and
function of MSCs. Hypoxic condition appears to enhance MSCs proliferation, differentiation,
and immune regulatory performance in damaged tissues without affecting its characteristic.
However, there are also studies that report on negative effects of hypoxia in MSCs.
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